BLUE Overview
Upcoming Projects (BLUE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BLUE)
-
Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Sep 11, 2024 at 04:00 PM EDT -
A Third Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP, BLUE
Executed On: May 02, 2024 at 02:00 PM EDT -
Follow-up Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: May 02, 2024 at 10:00 AM EDT -
A Second Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP, BLUE
Executed On: May 01, 2024 at 02:00 PM EDT -
Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Tickers: VRTX, CRSP, BLUE
Executed On: Apr 24, 2024 at 12:00 PM EDT -
A Second Look: Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Dec 21, 2023 at 01:00 PM EST -
Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Dec 19, 2023 at 01:00 PM EST -
An up to date look at exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP, BLUE
Executed On: Sep 07, 2023 at 10:00 AM EDT -
A second look: Discussing the potential of gene therapies such as exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP, BLUE
Executed On: Apr 14, 2023 at 09:00 AM EDT -
A review of EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: EDIT, VRTX, BLUE, CRSP
Executed On: Mar 13, 2023 at 02:00 PM EDT -
A second look at the FDA decision to lift the hold on Bluebird Bio's lovotibeglogene autotemcel (lovo-cel) sickle cell disease therapy
Ticker: BLUE
Executed On: Jan 23, 2023 at 03:00 PM EST -
A look at the FDA decision to lift the hold on Bluebird Bio's lovotibeglogene autotemcel (lovo-cel) sickle cell disease therapy
Ticker: BLUE
Executed On: Jan 18, 2023 at 07:00 PM EST -
A First Look at Zynteglo as a treatment for beta thalassemia
Ticker: BLUE
Executed On: Sep 16, 2022 at 11:30 AM EDT
Upcoming & Overdue Catalysts (BLUE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BLUE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
